A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
Clinical trial NCT04533490 · UNKNOWN
Trial details
- NCT number
- NCT04533490
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-01
- Primary completion
- 2022-10-01
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.